Medtronic's MiniMed Upgrade: Play the Diabetes Upgrade Into 45 Trading Days
We initiate a trade idea on Medtronic (MDT) as a mid-term buy centered on momentum in the MiniMed diabetes platform. Attractive yield, healthy free cash flow ($5.43B), and valuation metrics (PE ~22, EV/EBITDA 13.5) underpin the setup. Entry $83.21, stop $76.00, target $95.00 over 45 trading days.